| Accession | SAMC2792196 |
|---|---|
| Accession in Other Database | GSA-Human: HRS849536 |
| Sample name | P13_T_A |
| Title | Human esophageal carcinoma |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | Patient13_Tumor tissue_After Treatment |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA004740 in the GSA-Human system. |
| Release date | 2023-06-16 |
| BioProject Accession | PRJCA016745 |
| Submitter | Qiang Lu (luqiang@fmmu.edu.cn) |
| Organization | Air Force Medical University |
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA004740 (Controlled Access) | This study enrolled 22 patients diagnosed with stage II to IV ESCC, of whom 20 underwent neoadjuvant tislelizumab combined with chemotherapy before surgical removal and two were treated with camrelizumab plus chemotherapy before surgery. The dataset performed single-cell transcriptomic data of a total of 259,003 cells derived from 22 baseline and 24 post-NAT treatment samples of 22 stage II/III resectable ESCC patients. |